Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Drug Discov Today. 2012 Jul;17(13-14):741-7. doi: 10.1016/j.drudis.2012.02.009. Epub 2012 Feb 25.
In this article we discuss the novel pharmacological aspects of 5-HT(3) receptor antagonists. Commonly used to counteract chemotherapy-induced emesis, these agents now appear to be reaching out for newer indications. Studies have reported neuroprotective and anti-inflammatory properties in vitro and in vivo. 5-HT(3) receptor antagonists can modulate the immune-inflammatory axis through blockade of 5-HT(3) receptors present on immune cells. We review evidence addressing the effects of these drugs on peripheral inflammatory diseases, including asthma, rheumatoid diseases, inflammatory bowel disease and sepsis in addition to diabetes and CNS disorders, including Alzheimer's disease (AD), seizure and stroke.
本文讨论了 5-HT（3）受体拮抗剂的新药理学方面。这些药物通常用于对抗化疗引起的呕吐，但现在似乎有了新的适应证。研究报告称，它们在体外和体内具有神经保护和抗炎作用。5-HT（3）受体拮抗剂可以通过阻断免疫细胞上的 5-HT（3）受体来调节免疫炎症轴。我们回顾了这些药物对哮喘、类风湿性疾病、炎症性肠病和败血症等外周炎症性疾病以及糖尿病和包括阿尔茨海默病（AD）、癫痫和中风在内的中枢神经系统疾病的影响的证据。
